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We have shown that the tumor microenvironment of sporadic breast cancer is diverse in genetic alterations and
contributes to the cancer phenotype. The dynamic morphology of the mammary gland might be of special interest
in hereditary breast/ovarian cancer syndrome (HBOC). We hypothesized that hotspots of loss of heterozygosity or
allelic imbalance (LOH/AI) within the tumor stroma of BRCA1/2-related breast cancers provide an impaired
mammary stroma that could facilitate later malignant transformation of the breast epithelium. We conducted a
total genome LOH/AI scan of DNA derived from the epithelium and stroma of 51 BRCA1/2-related breast cancers,
using 372 microsatellite markers. We compared these data with those from a set of 134 sporadic breast cancers.
HBOC-related breast cancers accumulated signiﬁcantly more genetic alterations than did sporadic breast cancers.
BRCA1/2-related breast cancer stroma showed LOH/AI at 59.7% of all loci analyzed, similar to the average
frequency of LOH/AI observed in the epithelium (66.2%). This is remarkably different from sporadic breast cancers,
for which the average epithelial LOH/AI frequency (36.7%) far exceeds the average stromal LOH/AI frequency
(28.4%) ( ). We identiﬁed 11 hotspot loci of LOH/AI in the BRCA1/2 stroma, encompassing genes suchPp .03
as POLD1, which functions in DNA replication, and SDHB. In a subset of samples, enriched for BRCA1 cases,
we found 45.0% overall LOH/AI in the stroma, which was signiﬁcantly higher than the 41.8% LOH/AI observed
in corresponding epithelium ( ). Together, our data indicate that, in HBOC-related breast cancers, thePp .04
accumulation of genomic instability in the cancer stroma coincides with that in the neoplastic epithelium, and we
postulate that such a genetically unstable stroma might facilitate a microenvironment that functions as a landscaper
that promotes genomic instability in the epithelium and, subsequently, neoplastic transformation.
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In 2005, 1200,000 new cases of invasive breast cancer
were diagnosed, and ∼40,410 women died of this disease
in the United States alone. Different factors, environ-
mental as well as intrinsic, are associated with an in-
creased lifetime risk of breast cancer, estimated to be
13% in the general female population.1 This relative risk
is increased fourfold if familial disease or germline mu-
tations in breast cancer susceptibility genes are present
(breast cancer, familial [MIM #114480]). Germline mu-
tations in one of the two most common breast can-
cer susceptibility genes—BRCA1 (MIM 113705) on
17q21 and BRCA2 (MIM 600185) on 13q12.3—are
estimated to occur in 1 in 250 women overall,2 with the
frequency increasing to 5%–10% among women who
present with breast cancer.2,3
BRCA1 and BRCA2 have key regulatory roles in cru-
cial cellular events, such as response to DNA damage,
cell cycle regulation, and apoptosis.2 BRCA gene par-
ticipation in the DNA repair machinery is supported by
studies showing an elevated incidence of genomic insta-
bility in tumor tissue of hereditary breast cancer com-
pared with sporadic breast cancer. While the majority
of published reports have focused on selected chromo-
somal regions, two pangenomic transcriptional and
structural studies have been performed.4,5 These studies
identiﬁed regions with high frequencies of genomic
instability and allowed the differentiation between
BRCA1- and BRCA2-derived cancers based on copy-
number changes in a set of genomic loci or gene tran-
scription proﬁles. These studies, however, only looked
at whole tumors, without regard to their components.
A few studies even looked at the frequency of loss of
heterozygosity at a few selected markers in microscop-
ically normal-appearing breast tissue from a handful of
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patients with HBOC and found elevated levels of allelic
loss.6,7 Whereas some of the increased breast cancer risk
can be attributed to direct effects of germline mutation
within breast epithelial cells, it is equally plausible that
mutation of adjacent stromal cells creates an abnormal
microenvironment permissive of outgrowth of prema-
lignant and malignant epithelial clones. In this model,
local stromal-epithelial interactions, as codetermined by
both stromal and epithelial genotypes, determine the
likelihood of tumor formation.
Why is the tumor stroma important in hereditary
breast carcinogenesis? Morphogenesis of the branching
tree-like architecture of the breast begins during puberty
with ﬁrst lobule formation, a process that requires co-
ordinated interaction with the intralobular matrix
(stroma) comprised of ﬁbroblasts, blood vessels, lym-
phocytes, and macrophages. Duct branching and acinar
growth, which occurs during the ﬁrst decades of life, is
a primarily proliferative process orchestrated in con-
junction with changes in the stroma. Cancer-free women
who undergo prophylactic mastectomy because of a
family history of breast cancer have an altered breast
lobular architecture showing less differentiated lobules
(termed “Lob 1”), compared with controls with a more
dense and ﬁbrotic intralobular stroma that loses its de-
marcation from the collagenous interlobular stroma.8
This is direct evidence that a change in epithelial and/
or stromal cell function, such as that conferred by her-
itable mutation, is capable of upsetting the delicate bal-
ance of breast tissue morphogenesis. Remodeling of
breast lobules continues in adulthood under hormonal
control. This is most evident during pregnancy, when
the density of acini increases dramatically and epithelial
lining cells undergo secretory differentiation.
In this study, we embarked on a whole-genome anal-
ysis of breast cancer in patients with and without
BRCA1/2 mutations and sought to determine the extent
of genomic instability in the malignant breast epithelium
and in the adjacent tumor stroma and how the genomic
instability differs from that in sporadic breast cancers.
This question is not purely of scientiﬁc interest. Discov-
ery of potential hallmarks of stromal cell genomic in-
stability in these heritable breast cancers might provide
a means to stratify future cancer risk among patients
with familial clustering of breast cancer.
Material and Methods
Sample Population
A total of 51 invasive breast cancers from 51 patients with
hereditary breast and/or ovarian cancer (HBOC) were accrued
for this study, and a meticulous family history of all 51 patients
was obtained and documented. We will refer to this series as
“BRCA1/2-related”; it comprises patients with germline del-
eterious mutations in BRCA1 ( ) or BRCA2 ( ),np 22 np 13
patients with germline unclassiﬁed variants in BRCA1
(BRCA1uv; ) or BRCA2 (BRCA2uv; ), and twonp 6 np 8
patients with HBOC who are wild type for both genes
(BRCAwt) (tables 1 and 2). Besides mutation analysis, the
diagnosis of HBOC was determined on the basis of HBOC
criteria and clinical practice guidelines for all families.9 The
human subjects review boards of the respective participating
institutions approved this study. One patient, harboring a
BRCA2 deleterious mutation, underwent prophylactic mas-
tectomy. To compare data from the BRCA1/2-related cancers
with data from sporadic breast cancers, our previously re-
ported10 data set comprising data from 134 clinically sporadic
stage 1–3 invasive breast carcinomas was reanalyzed.
Laser Capture Microdissection and DNA Extraction
Laser capture microdissection was performed using the Arc-
turus PixCell II microscope (Arcturus Engineering) to isolate
the two compartments of neoplastic tissue (epithelium and
stroma) separately.10,11 We speciﬁcally captured stromal ﬁ-
broblasts adjacent to malignant epithelium (i.e., the tumor
stroma), under direct microscopic observation. These stromal
ﬁbroblasts resided either in-between aggregations of epithelial
tumor cells or no more than 0.5 cm distant from a tumor
nodule. Unlike enrichment procedures, such as cell-type spe-
ciﬁc separation of cells previously dissociated from large tissue
samples, microscopic dissection is able to control for proximity
of stroma to cancer cells among all samples. Corresponding
normal DNA for each case was procured from peripheral
blood leukocytes (possible for 63%) or, if this was not possible,
from normal tissue, obtained a large distance from the tumor
site or from a different tissue block containing only normal
tissue. The different origins of the corresponding normal DNA
had no effect on the frequency or pattern of loss of hetero-
zygosity or allelic imbalance (LOH/AI)
Genomewide LOH/AI Scan
Genomic DNA was extracted as described elsewhere,10–12
with the exception that an incubation with proteinase K was
performed at 65C for 2 d. PCR was performed using DNA
from each compartment (normal control, tumor epithelium,
and tumor stroma) of each sample and one of 72 multiplex
primer panels, which comprised 372 ﬂuorescent labeled mi-
crosatellite markers. These 372 markers map to chromosomes
1–22 and X and are based on the MapPairs genomewide Hu-
man Markers set, version 10 (Invitrogen), developed at the
Marshﬁeld Institute. This whole-genome panel has an average
of 16.2 markers per chromosome (range 7–29 markers per
chromosome), or an ∼9-cM intermarker distance.
Genotyping was performed with the ABI 377xl or 3700
semiautomated sequencer (Applied Biosystems, Perkin-Elmer).
The results were analyzed by automated ﬂuorescence detection
using the GeneScan collection and analysis software (Applied
Biosystems). Scoring of LOH/AI was performed by manual
inspection of the GeneScan output. A ratio of peak heights of
alleles between germline and somatic DNA of 1.5 was used
to deﬁne LOH/AI, as described elsewhere by us and oth-
ers.13–15 As described elsewhere, the methodological veracity
of LOH/AI by use of multiplex PCR on archived tissue has
been extensively validated.10
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Table 1
Mutation Spectra of Samples from 35 Patients with HBOC and Deleterious
Mutations
SAMPLE MUTATION DOMAIN
D17S1299 D13S1493
EP ST EP ST
1 BRCA1 4020delAG SCD … … … …
4 BRCA1 IVS41GrT … … … … …
5 BRCA1 185delAG RING ﬁnger X X … …
6 BRCA1 1135insA … X … X …
7 BRCA1 185delAG RING ﬁnger … … … …
8 BRCA1 2530delAG DNA binding … … … …
9 BRCA1 3600del11 … … X … X
10 BRCA1 IVS182delA … X X … …
11 BRCA1 1240delC … X X … …
12 BRCA1 589delCT … … X … …
17 BRCA1 IVS183A/C … … … … …
19 BRCA1 1389insAG … … X … X
20 BRCA1 IVS61C/T … X … X …
21 BRCA1 del ex23–24 BRCT X X X …
22 BRCA1 IVS183A/C … X X X X
23 BRCA1 del ex23–24 BRCT … X … …
24 BRCA1 157delCT RING ﬁnger … … … …
25 BRCA1 4229insATCT SCD X X … …
37 BRCA1 5385insC BRCT … … … …
50 BRCA1 2552delC DNA binding X … … X
51 BRCA1 C61G RING ﬁnger X … X …
52 BRCA1 IVS511TrG … … X X …
2 BRCA2 2567delC … X … X …
3 BRCA2 6174delT … X … … …
13 BRCA2 Y1894X … X X … …
14 BRCA2 6503delTT … … … … …
15 BRCA2 6503delTT … … … … X
16 BRCA2 8294insTT … … … … X
26 BRCA2 5804delAAAA … … … … …
29 BRCA2 8234delTT … … … … …
36 BRCA2 5578delAA … … … X X
44 BRCA2 8234del23 … … … … …
45 BRCA2 5804delAAAA … … … X …
46 BRCA2 8765delAG … … … … …
49 BRCA2 3036delACAA … … X … …
NOTE.—D17S1299 is a marker at the BRCA1 locus, and D13S1493 is a marker
at the BRCA2 locus. BRCT p C-terminal portion of the BRCA1 gene; EP p epi-
thelium; SCD p stromalin conservative domain; ST p stroma. “X” indicates LOH/
AI for that sample in the corresponding compartment.
Statistical Analysis
Of the 372 markers, 1 was excluded from further statistical
analyses because it was noninformative in all epithelial samples
or all stromal samples. Statistical analysis was performed for
samplewise, chromosomewise, and markerwise LOH/AI fre-
quencies. Comparisons made included those between normal
control and tumor epithelial and stromal samples, between
different chromosomes, and between markers on the same
chromosome. Two levels of analyses were employed: simple
averaging of observed LOH/AI frequencies and model-based
analysis. The former is straightforward and provides useful
data summaries as well as suggests interesting patterns and
differences. For the latter, we employed marginal models that
extend generalized linear models to correlated data. The re-
sulting inference is robust because a sandwich-type estimator
for the variance matrix was used. We have reported this ap-
proach in detail elsewhere.10 Hierarchical clustering and mul-
tidimensional scaling were performed using the proportion of
discordant LOH/AI events between a pair of samples as the
dissimilarity measure. All data analysis was performed using
the statistical package R, version 1.8.1 (The R Foundation for
Statistical Computing). For comparisons between groups, the
x2 tests with Yate’s correction and the nonparametric Spear-
man rank correlation test were used.
Results
Of the 51 patients with HBOC, 2 are wild type for
BRCA1/2 but show a strong family history of breast and
ovarian cancers (ﬁg. 1). Among the 49 patients with
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Table 2
Samples from 16 Patients with HBOC and without
the Deleterious Mutations in BRCA1/2
Sample Genotype Effect
27 BRCA1uv N1236K Unclassiﬁed
28 BRCA1uv S1040N Unclassiﬁed
39 BRCA1uv A1623G Unclassiﬁed
41 BRCA1uv IVS214TrC Unclassiﬁed
43 BRCA1uv S1040N Unclassiﬁed
47 BRCA1uv S1623G Unclassiﬁed
30 BRCA2uv A2466V Unclassiﬁed
31 BRCA2uv IVS856TrC Unclassiﬁed
32 BRCA2uv IVS2111A/C Unclassiﬁed
33 BRCA2uv A2951T Polymorphism
35 BRCA2uv I3412V Unclassiﬁed
38 BRCA2uv K1057R Unclassiﬁed
40 BRCA2uv A2466V Unclassiﬁed
42 BRCA2uv A2951T Polymorphism
34 BRCA1/2wt Wild type
48 BRCA1/2wt Wild type
Figure 1 Pedigree of a family with HBOC segregating BRCA variants. The pedigree is shown across 4 generations, with affected members
(with breast cancer) indicated by blackened circles. The proband (arrow) was diagnosed with breast cancer at age 49 years, and testing showed
her as wild type for both BRCA genes. Other affected family members (stars) tested positive for the BRCA1 Ser1040Asn and BRCA2 Ser2483Gly
variants.
germline variants in either BRCA1 or BRCA2, 35 have
mutations considered deleterious on the basis of the
Breast Cancer Information Core database and recent
publications (table 1). The analyses of the demographic
data show that the average age at onset for the BRCA1
group was 39.1 years, signiﬁcantly lower than that for
the BRCA2 group (50.8 years; ). Our studyPp .031
also showed a strong positive correlation between es-
trogen (ER) and progesterone (PR) receptor status and
type of mutation ( and .013, respectively), withPp .003
a higher frequency of ER-positive and PR-positive cases
in the BRCA2 group (37.5% ER positive; 50% PR pos-
itive) than in the BRCA1 group (17.6% ER positive;
17.6% PR positive; ), as expected. High-Pp .0496
grade tumors (grade 3) occurred more frequently in the
BRCA1 group (66.6%) than in the BRCA2 group
(37.5%). Forty-eight tumors were classiﬁed as invasive
ductal carcinoma, one as an invasive lobular carcinoma
(BRCA1uv), and one as a ductal carcinoma in situ
(BRCA1uv). In our data set, we found LOH/AI at 17q21
(BRCA1 locus) signiﬁcantly more often in patients with
a BRCA1 mutation than in those with a BRCA2 mu-
tation ( ) (table 1). Interestingly, while 68.2%Pp .0318
of all BRCA1 cases show LOH/AI in either the neo-
plastic epithelium and/or stroma, in ﬁve cases (22.7%),
the allelic loss is conﬁned to the stromal compartment
(table 1). Thus, overall, our sample set is consistent with
other reports, showing a lower frequency of ER/PR-pos-
itive status, lower age at onset, higher frequency of grade
3 tumors, and loss of one functional BRCA1 allele
among BRCA1 mutation–positive patients.16
Frequency and Pattern of LOH/AI in Breast Carcinoma
Epithelium and Surrounding Stroma from HBOC Cases
Genomic instability, as manifested by LOH/AI, was a
frequent event in our series ofBRCA1/2-related (HBOC)
breast cancers, occurring in 63.0% of all informative
markers, exceeding the overall frequency of 32.6%
LOH/AI found in sporadic breast cancers ( ).P ! .0001
The frequency of LOH/AI is approximately equal in the
neoplastic epithelium (66.2%) and corresponding sur-
rounding stroma (59.7%; ) of HBOC cases. InPp .17
contrast, sporadic breast cancers show a signiﬁcantly
higher frequency of LOH/AI in the epithelium (36.7%)
than in the stromal compartment (28.4%; )10Pp .037
(ﬁg. 2). Notably, breast cancer epithelial and stromal
cells from individuals with deleterious mutations in
BRCA1/2 and those with BRCA1/2uv showed a similar
degree of overall genomic instability.
To evaluate for any speciﬁc patterns of LOH/AI, we
employed an unsupervised hierarchical cluster analysis
based on 371 microsatellite markers and 51 breast can-
cers from probands with HBOC. For each patient, the
epithelium and stroma of breast carcinoma was consid-
ered separately (i.e., as two samples for each patient),
giving us 102 end branches (ﬁg. 3). Because the analysis
was performed without any presumption about the
grouping of these samples, the global pattern of LOH/
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Figure 2 Frequency of LOH/AI observed in the epithelium and stroma in HBOC-related breast cancer compared with sporadic breast
cancers. Frequency of LOH/AI (Y-axes) is plotted on a markerwise level (X-axes). The average LOH/AI frequency of markers in the epithelium
(top panel) and stroma (bottom panel) are shown for 51 cases of HBOC-related breast cancer (blue dots) and 134 cases of sporadic breast
cancer (red dots). The bold horizontal lines indicate LOH/AI frequencies averaged over all markers.
AI would cluster similar samples close to each other on
the basis of the pattern of LOH/AI observed for all 371
loci. The analysis reveals no distinct separation of
BRCA1 and BRCA2 samples nor of the BRCA1/2 var-
iants considered deleterious and those of unknown effect
(BRCA1/2uv) into individual clusters. Also, no separa-
tion of tumor epithelium and stromal samples occurred.
However, we noted a subset of BRCA1 samples that
clustered close together (ﬁg. 3). Part of this subset con-
sists of 15 patients whose epithelium and matching
stroma cluster directly together. This means that, for
these 15 patients, the pattern of LOH/AI in the epithe-
lium is more similar to the pattern of LOH/AI observed
in the corresponding stroma of the same patient than to
any other sample. Among this group of 15 patients,
BRCA1 cases are signiﬁcantly overrepresented (10 of 15
cases; ). In contrast to almost half (45.5%) ofPp .028
all BRCA1 patients, only 2 (15.4%) of 13 BRCA2 sam-
ples showed this similarity in LOH/AI between epithe-
lium and stroma ( ). Because the hierarchicalPp .07
cluster analysis is limited to one dimension, we also used
two-dimensional scaling to visualize the relation be-
tween samples (ﬁg. 4). Here, we note that both BRCA1/
2 samples and those from patients with BRCA1/2uv are
contained in a similar region within this two-dimen-
sional space. In addition, the location and therefore the
pattern of LOH/AI of the two clinical HBOC cases with
wild-type BRCA1/2 overlaps with all the other HBOC
cases. However, using two-dimensional scaling, we again
noted that a subset of predominantly BRCA1 samples
grouped in a distinct region (ﬁg. 4), similar to what we
observed using unsupervised hierarchical clustering (see
above and ﬁg. 3).
Hotspots of LOH/AI in the Epithelium and Stroma
of BRCA1/2-Related Breast Carcinomas
We then set out to detect nonrandom (hence, hotspot)
LOH/AI occurring in BRCA1/2-related breast cancer ep-
ithelium and stroma and to correlate these with pre-
senting clinico-pathologic features. Potential hotspots of
LOH/AI were identiﬁed for 11 loci on six chromosomes
in the epithelium and in 10 loci on six chromosomes in
the stroma (table 3). These hotspot loci showed signif-
icantly elevated LOH/AI frequencies compared with
those of the rest of the chromosome (table 3). Of note,
the hotspot LOH/AI loci in BRCA1/2-related breast can-
cer epithelium and stroma are distinct from those we
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Figure 3 Unsupervised hierarchical cluster analysis. Average linkage and the dissimilarity measure of proportion of discordant LOH/AI
between samples are used. The analysis was based on the presence or absence of LOH at 371 informative loci for 51 HBOC-related breast
carcinoma epithelial samples and the matching 51 stromal samples (for a total of 102 end branches). The numbers at each end branch indicate
germline deleterious mutations in BRCA1 (1) or BRCA2 (2) or unclassiﬁed variants of these genes (uv1 and uv2, respectively). The stars indicate
those samples for which the stroma and epithelium of one case cluster directly together. Note the clustering of BRCA1 samples near the left
(black bar; see text for details). wt p Wild type.
previously identiﬁed in sporadic breast cancers.10 For
example, in sporadic breast cancer, hotspots of geno-
mic instability were found at 11q22.3 in the epithelium,
compared with 11q24.1 in BRCA1/2-related breast can-
cer epithelium. Interestingly, while, in sporadic breast
cancer, this 11q22.3 hotspot was tightly ﬂanked by
regions that retained heterozygosity, inBRCA1/2-related
breast cancers, we commonly ﬁnd that the 11q24.1
LOH/AI hotspot extends some distance centromerically
to 11q22.3.
We examined whether the presence of LOH/AI at
these hotspot loci in the epithelium and/or stroma cor-
related with presenting clinico-pathologic status or
germline mutation status. LOH/AI at 12q23.2 in the
epithelium occurred signiﬁcantly more often in tumors
of stage pT2–4 than in pT1 tumors ( ). In ad-Pp .043
dition, LOH/AI at 20p11.2 in stroma appears to be
associated with the presence of unclassiﬁed variants
( ).Pp .004
LOH/AI in the Epithelium and/or Stroma of BRCA1/2-
Related Breast Cancer Compared with Sporadic Breast
Cancer
In the next step, we focused on those cases with del-
eterious BRCA1/2 germline mutations. To elucidate the
relationship of BRCA1 and BRCA2 to each other as
well as to sporadic breast cancers, we performed mul-
tidimensional scaling, looking separately at the neo-
plastic epithelium and at the stromal compartment (ﬁg.
5). We found thatBRCA1 and BRCA2 samples grouped,
to some degree, in a similar space in this two-dimen-
sional plot. The LOH/AI pattern of BRCA1/2 neoplastic
epithelium overlapped, to a great extent, with that ob-
served in the epithelium of the sporadic counterparts (ﬁg.
5). In striking contrast, however, we found that there
was a stronger separation between BRCA1/2-related
samples and sporadic ones, when looking at the stromal
compartment (ﬁg. 5).
Knowing that stroma and epithelium have a close in-
teraction during carcinogenesis, we then combined both
LOH/AI data sets (from epithelium and stroma) of 51
cases of HBOC and 134 cases of sporadic breast cancer
and performed unsupervised cluster analysis (ﬁg. 6). On
the basis of this combined epithelium and stroma data
set, we noted a strong clustering of HBOC cases. How-
ever, we found that 11 cases with germline BRCA1/2
mutations grouped outside the strong HBOC cluster.
This effect was also observed, to varying extents, in the
previous analysis (as illustrated in ﬁgs. 3 and 4). The
uniqueness of these samples is revealed when we look
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Figure 4 Two-dimensional scaling of 51 HBOC-related breast
cancer cases. Each case is represented by combining the stroma and
malignant epithelium from the same patient. Samples were obtained
from individuals with germline mutations in BRCA1 (black dots) or
BRCA2 (red dots), with variants in BRCA1 (BRCA1uv [green dots])
or BRCA2 (BRCA2uv [blue dots]), or without mutations or variants
in either gene (yellow dots). Note the clustering of samples with
BRCA1 mutations to the left of the diagonal line.
Table 3
Hotspots of Genomic Instability in the Epithelium and Stroma
of BRCA1/2-Related Breast Carcinomas
Tissue
and Locus Marker P Gene(s)
Epithelium:
1p36.13 D1S3669 .0185 TP73, SDHB
1p21.1 ATA42G12 .0234
1q23.1 D1S1653 .0135 FCRL2
1q42.3 D1S235 .0402 GNG4
11q24.1 D11S4464 .0108 LOH11CR2A, ETS1,
NFRKB
11q24-25a D11S4463 .0062
12q23.2 PAH .0149 PAH, ASCL1, IGF1
14q23.1 D14S592 .0274 SIX1
20p12.1-11.23 D20S1143 .0097 RBBP9, SNRPB2,
PCSK2
20q13.32 D20S164 .0196 RAB22A
Xp22.2 DXS9902 .0038 FANCB, BMX, STS
Stroma:
1p36.13 D1S3669 .0447 TP73, SDHB
1p21.1 ATA42G12 .0193
1q42.3 D1S235 .006 GNG4
7p14.1 D7S2846 .0178 SFRP4
10p11.21 D10S1208 .0268 CUL2, CREM
18q21.32 D18S1357 .0397 BCL2, DCC
18q23 D18S1390 .0237
19q13.33 D19S246 .0031 POLD1
20p13 D20S482 .0326 SMOX, RASSF2,
SLC23A2
20q13.32 D20S164 .0492 RAB22A
a Mapped between D11S4464 and D11S1304.
at the overall frequency of LOH/AI in this group of 11.
We found that the samples that are consistently outliers
(denoted as “group 1”) showed an average LOH/AI fre-
quency of 41.8% in the epithelium and 45.0% in the
stroma, compared with LOH/AI frequencies of 72.9%
and 64.0% in the epithelium and stroma, respectively,
of the remaining group of HBOC cases (denoted as
“group 2”). Although the frequencies of LOH/AI in
these two groups are signiﬁcantly different in the epi-
thelium ( ), the difference was not statisticallyPp .046
signiﬁcant for the frequencies observed in the stroma
( ).Pp .25
Discussion
The elucidation of the functional properties of BRCA1/
2 germline mutations and their role in carcinogenesis of
HBOC syndrome allowed genetic testing for cancer sus-
ceptibility in members of affected families. However,
classic HBOC-affected families exist that lack germline
deleterious mutations in the BRCA1/2 genes or other
breast cancer susceptibility genes. This implies that other
factors, yet unknown to us, are contributing to breast
cancer risk. Therefore, one of the questions to be an-
swered is, Are breast cancers derived from individuals
with BRCA1 or BRCA2 mutations and non-BRCA1/2
cases of breast cancer distinct diseases at the somatic
genetic level, or do they share key genetic aspects in
carcinogenesis?
The important role of the tumor microenvironment,
both at the genetic and cell biological level, in the ini-
tiation and progression of sporadic breast cancer has
been shown elsewhere by us and others.10–12,17–20 In fact,
a recent animal model suggests that the process of car-
cinogenesis can be normalized through manipulation of
stromal-mediated mechanisms.19 In our current study,
we isolated the malignant breast epithelium and its sur-
rounding stroma separately, which allowed us, for the
ﬁrst time, to portray a comprehensive genomic picture
of the tumor microenvironment. Our data suggest that,
indeed, in patients withBRCA1/2-related breast cancers,
genomic alteration in the stroma coexists equally with
that in the epithelium, and, thus, the genetically unstable
stroma might provide for a microenvironment that func-
tions as a landscaper that positively selects for genomic
instability in the epithelium, thereby promoting neo-
plastic transformation.
High Frequency of LOH/AI in Stroma Suggesting
Landscaping Role
We noted the overall high frequency of genomic in-
stability in the epithelium and stroma of all samples with
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Figure 5 Multidimensional scaling of LOH/AI patterns from 35 patients with deleterious BRCA1/2 mutations. The LOH/AI patterns
from epithelium (EP; left panel) and stroma (ST; right panel) of individuals with germline mutations in BRCA1 (black dots) and BRCA2 (red
dots) were analyzed separately in the context of the pattern of LOH/AI observed in sporadic breast cancers (green dots). Note that the stromal
LOH/AI pattern differentiates BRCA1 and BRCA2 mutation-positive breast cancers from sporadic breast cancers.
HBOC, regardless of the germline BRCA1/2 mutation
status. In comparing them with our cases of sporadic
breast cancer, we therefore conclude that predisposition
to genomic instability, as manifested by high frequencies
of LOH/AI, is a unifying factor in BRCA1/2-related and
non–BRCA1/2-related HBOC breast cancers. Interest-
ingly, in HBOC breast cancers, we note that, not only
the malignant epithelium, but also the stroma harbors
a similarly high frequency of genomic instability. The
potentially important role of the stroma in HBOC car-
cinogenesis is corroborated by morphological observa-
tions during mammary development. The process of
mammary differentiation requires not only extensive cell
proliferation but also penetration of the breast epithe-
lium at the ductal end buds into the stroma. On the basis
of clinical epidemiologic observations, one can hypoth-
esize that, as the mammary mesenchyme proliferates
during puberty, it is already affected by the impaired
DNA repair mechanism resulting from defective BRCA
genes, and so somehow predisposes to the highly sus-
ceptible, proliferating mammary epithelium during preg-
nancy.21 This idea is supported by the data from our
patient with a germline BRCA2 mutation who received
prophylactic mastectomy. Histological examination by
two pathologists conﬁrmed that the breast tissue ana-
lyzed in our study did not contain any signs of atypia.
We already found LOH/AI in 31.5% of all informative
markers in the microscopically normal-appearing breast
epithelium (compared with germline/blood DNA). Such
a high frequency of genomic alterations in normal-ap-
pearing tissue might be surprising at ﬁrst but can be
explained by the impaired DNA repair machinery. This
ﬁnding is supported by a report by Cavalli et al.,6 who
analyzed normal tissue of ﬁve patients with BRCA mu-
tations and found LOH/AI in 50% of the 15 loci ana-
lyzed. Interestingly, the stromal ﬁbroblasts of the pro-
phylactic mastectomy specimen showed LOH/AI in
165.5% of all informative markers, which was not dif-
ferent from the frequency of LOH/AI observed in the
tumor stroma of breast cancers among the other HBOC
cases. A similar observation is made when we look at
the subset of cases (group 1) that showed a lower overall
frequency of genomic instability in the neoplastic epi-
thelium; their corresponding stroma showed a higher
overall LOH/AI frequency, statistically similar to that
observed in group 2 (which had higher overall LOH/AI
frequencies in both stroma and epithelium). Such an ob-
servation could be interpreted in two ways—either that
stromal genomic instability precedes that in the epi-
thelium in some BRCA1/2-related breast cancers, and
therefore stroma accumulates more genetic alterations,
or that at least two distinct progression pathways exist,
leading to two distinct phenotypes, one with high-level
and the other with low-level genomic instability within
the breast cancer epithelium.
Clonal Patches in Genetically Unstable Stroma
and Epithelium
Our data show that genetically unstable cell popula-
tions collected over large expanses of microdissected tis-
sue (e.g., epithelium or stroma) share LOH/AI patterns
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Figure 6 Unsupervised cluster analysis by LOH/AI status in a combined stromal and epithelial data set for HBOC-related breast cancers
and sporadic breast cancers. HBOC breast cancers are labeled at the end branches with “DM” (deleterious mutation) and “non-DM” (comprising
those with variants of unknown signiﬁcance and those without detectable mutations). The bar below the cluster plot visualizes the separation
of HBOC breast cancers (black and gray bars) from sporadic breast cancers (white bars).
among cells, suggesting clonal expansion of the affected
cells. Much of this conclusion is based on the technical
limitations of LOH/AI analysis, which is not capable of
detecting allelic imbalance without a majority (150%)
of the sample contributing to the shared altered geno-
type. Such conservation of speciﬁc genetic alterations
across many spatially distributed cells is a characteristic
feature of (benign and malignant) neoplastic processes
in which a geographic clonal expansion of mutated cells
occurs, with exclusion of unaffected wild-type cells.22
The monoclonal character of tumor stroma, as docu-
mented by conserved locus-speciﬁc LOH/AI, is compel-
ling evidence that the stroma itself is neoplastic and
capable of overrunning, or outcompeting, genetically in-
tact stromal cells. This is one mechanism for local en-
richment of genetically altered stromal cells, which may
increase the magnitude of their functional impact on
adjacent breast epithelium.22 Alternatively, one might
propose that stromal ﬁbroblasts could be subjected to
apoptosis as a result of an increased rate of DNAdamage
due to loss of BRCA1/2 function. Those cells evading
apoptosis might, therefore, gain a growth advantage;
thus, the consequent clonal expansion could be viewed
as a result of a repair mechanism.
Hotspots of Genomic Instability in the Epithelium
and Stroma
In addition to a general genomic instability, we iden-
tiﬁed a similar number of LOH/AI hotspots in the epi-
thelium (11 loci) and stroma (10 loci) of HBOC breast
cancers, which contrasts our observations in sporadic
breast cancer, for which we identiﬁed 19 loci in the ep-
ithelium and 38 loci in the stroma (table 3). In sporadic
breast carcinomas, there is an overall higher frequency
of LOH/AI in the epithelium than in the stroma, which
suggested that epithelial genetic events initiate sporadic
breast carcinogenesis and, perhaps, that stromal genetic
events lend biological diversity.10 This is also reﬂected
by the diversity of genetic alterations. While BRCA1/2-
related stromal hotspot LOH/AI loci are more limited
(10 loci), each locus bears a signiﬁcantly higher fre-
quency of LOH/AI (average 77.35%  7.95%), com-
pared with sporadic breast cancer stromal hotspots,
which are diverse (38 loci) but possess a lower frequency
of LOH/AI (53.22%  7.36%). Notably, there is vir-
tually no overlap in the epithelial and/or stromal hotspot
loci observed in the HBOC breast cancers compared
with those observed in sporadic breast cancers.
We hypothesized, as outlined above, that the impaired
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stroma might have a landscaping role for the neoplastic
transformation of mammary epithelium. On the basis of
our data, we speculate that regulatory genes affecting
the microenvironmental organization, the cell-cell inter-
action, or the response to paracrine stimuli might be
altered and provide a basis for such an hypothesis. For
instance, we observed frequent loss of the SDHB locus
in the stroma and epithelium. Succinate dehydrogenase
complex, subunit B (SDHB [MIM*185470]), is involved
in mitochondrial electron transport and lies at the junc-
ture of the Krebs cycle, and loss of SDHB results in the
disruption of mitochondrial complex II and subsequent
transcription factor hypoxia inducible factor 1 (HIF1a
[MIM *603348]) activation. Increase in HIF1a in turn
leads to activation of the cell proliferation pathway and
to an increase in paracrine-acting growth factors, such
as vascular endothelial growth factor (VEGF [MIM
*192240]).23
In our series, we were able to associate genomic in-
stability at the PAH locus (12q23.2) in the epithelium
with higher T stage (T1 vs. T2, T3, and T4). The insulin-
like growth factor 1 gene (IGF1 [MIM *147440]) is
among the genes that map to this locus. IGF1 plays an
important role in the development of the differentiated
mammary gland, and elevated levels of IGF1 have been
associated with an increased risk of early breast cancer.
However, the absence of the common IGF1 19-repeat
allele (a CA repeat in the promoter region that occurs
in most white women) has been identiﬁed as a high-risk
genotype.24 Loss of this protective allelemight contribute
to advanced disease or contribute to the Lob 1 seen in
HBOC cases.
Another particular hotspot locus, at 19q13.33, is wor-
thy of mention. This region harbors POLD1 (MIM
*174761), which codes for a primary replicative enzyme
with proofreading capabilities.25 Its function during
DNA duplication at the replication fork creates single-
strand DNA regions.25,26 Impaired POLD1 can therefore
lead to single-strand gaps and double-strand breaks.26
The defective POLD1D400A is associated with cancer sus-
ceptibility,27 and a recent kin-cohort study found that a
variant of POLD1R119H (0.06% allelic frequency) was
associated with an approximately twofold increase in
the relative risk for sporadic breast cancer ( ).28Pp .058
These observations together with our ﬁndings of signif-
icantly elevated LOH/AI at the POLD1 locus are im-
portant, since they suggest a possible functional reason
for the high frequency of genomic instability observed
in the stromal compartment. This mechanism involving
POLD1 is restricted to carriers of deleterious BRCA1/
2 mutations as well as HBOC cases (with BRCA1/2uv
or no mutation), such that no LOH/AI hotspots at
19q13.33 were found in sporadic breast cancer stroma.
Previous studies have addressed LOH/AI frequencies
in breast cancers derived from HBOC cases and may
have reported relatively high frequencies of LOH/AI at
loci distinct from our hotspots. There are several
straightforward explanations for these apparent dis-
crepancies. First, it is important to note that our oper-
ational deﬁnition of a hotspot is based on our model-
based approach: a hotspot is deﬁned as having a
signiﬁcantly high frequency of LOH/AI, compared with
all other loci along the same chromosome.10 Thus, it is
possible that other studies using a small set of markers
might ﬁnd an apparently high frequency of LOH/AI in
one marker and label this locus signiﬁcant29; however,
other loci along the same chromosome, which may not
have been examined, might have LOH/AI at a similar
or even elevated level than the selected marker. Second,
studies using array-based comparative genomic hybrid-
ization, although they have the advantage of differen-
tiating between allelic gain and loss, usually detect losses
and/or gains of larger genomic regions, spanning several
BAC clones.5,16,30 Finally, another important factor that
allowed us to identify previously unrecognized hotspots
is the separation of neoplastic epithelium and stroma.
The previous studies have looked at the admixed (epi-
thelium and stroma) tumor tissue. Since our ﬁndings
indicate a high level of genomic instability in the stromal
compartment of HBOC-related breast cancers, we can
only assume that, in previous studies, only regions with
concordant allelic imbalance in epithelium and stroma
would have been identiﬁed as hotspots.
Epithelial-to-Mesenchymal Transition in a Subset
of BRCA1-Related Breast Cancers?
It has been shown recently that BRCA1-related breast
cancers commonly present with a “basal type” pheno-
type, identiﬁed by the expression of myoepithelial mark-
ers.16 Interestingly, a “basal type” gene-expression pat-
tern was associated with a subset of sporadic breast
cancers as well,31 implying that a subset of sporadic
breast cancers follow an oncogenic pathway similar to
that BRCA1/2-related cancers. In our study, we found
that the pattern of genomic instability observed in the
epithelium and stroma in a subset of 15 HBOC cases
(group 1) is so similar that the two compartments (ep-
ithelium and stroma) from a given individual cluster di-
rectly together. The majority of these samples are from
BRCA1 cases, commonly associated with the “basal
type” phenotype. We addressed the issue that such sim-
ilarity can potentially arise from admixed tissue (e.g.,
contaminating epithelial cells in the stroma fraction or
vise versa). Besides the great caution that was used dur-
ing the laser capture microdissection procedure, other
observations provide conclusive evidence against an er-
roneous ﬁnding. For one, in this set of 15 HBOC cases,
we noted markers with opposing LOH/AI calls in each
compartment of a given tumor (e.g., LOH/AI observed
www.ajhg.org The American Journal of Human Genetics Volume 78 June 2006 971
in epithelium but not stroma, and vice versa). In addi-
tion, in some cases with concordant LOH/AI calls, we
ﬁnd that different alleles are lost in a compartment-
speciﬁc manner. Third, we identiﬁed somatic mutations
in some of these 15 cases that were conﬁned to either
the epithelium or the stroma compartment.32 Since all
analyses were performed from the same pool of ex-
tracted DNA, such observations rule out the pos-
sibility of tissue admixture or intercompartmental
contamination.
In our previously reported analysis of sporadic breast
cancer, we noted a pattern in which the corresponding
epithelium and stroma cluster together in a few cases.10
For sporadic breast cancers, we believe that the small
subset of cases may suggest an epithelial-to-mesenchy-
mal transition. Whether the observation of tight epithe-
lium-corresponding stroma clustering in the subset of
BRCA1 cases also reﬂects epithelial-to-mesenchymal
transition is not known. Another hypothesis that might
warrant further exploration in this context is the concept
of cell fusion.33,34 In this theory, cell fusion is assumed
to be essential for the development and maintenance of
a clinically signiﬁcant tumor.33 Advanced breast cancer
is commonly associated with aneuploidy and thus a la-
bile genome, whereas cell fusion is thought to produce
polyploid cells that ultimately end up as small cells with
scarce or sparse cytoplasm.33 Interestingly, Roy et al.35
reported that 30.64% of all tumor metaphases of HBOC
cases were hyperdiploid.We therefore might hypothesize
that, in this subset of HBOC cases, the malignant breast
epithelial cells fuse with the stromal cells and, in reju-
venating the labile genome, result in further enhanced
genomic instability in both the epithelium and stroma.
Although this hypothesis is consistent with our current
observations, further proof will clearly require conﬁr-
mation by use of functional modeling. Similarly, while
our observation of the frequency and distribution of ge-
netic alterations in sporadic and HBOC breast cancers
is straightforward, the conclusion that the HBOC mam-
mary stroma has a landscaping role would require func-
tional modeling. With expansion of the approaches re-
ported by Shakar et al.20 and others,19 one intriguing
approach would be to obtain stromal ﬁbroblasts of
HBOC breast cancer and prophylactically operated
HBOC cases and to investigate their inﬂuence on mam-
mary epithelial cells in coculture. In addition, such an
in vitro model would allow testing of the co-contribution
of other paracrine-acting factors, such as IGF2 (MIM
147470) or estrogens.
Summary and Conclusion
In summary, our data show that, in contrast to stroma
of sporadic breast cancers, genomic alterations in the
stroma of BRCA1/2-related breast cancers are an im-
portant, unifying, and potentially driving mechanism in
the pathogenesis of breast cancer. We identiﬁed several
potential hotspots of genomic instability that occur not
only in carriers of deleterious BRCA1/2 mutations but
also in HBOC cases without obvious pathogenic mu-
tations (mutation-negative cases and cases with variants
of unknown signiﬁcance). These hotspots are distinct
from those identiﬁed in sporadic breast cancers,10 and
so our observations suggest that these HBOC-related
breast cancer hotspots are speciﬁc to the pathogenesis
of breast cancer in those with germline BRCA1/2 mu-
tations and in those whose clinical picture is consistent
withBRCA1/2 disease, even in the absence of pathogenic
mutations or the presence of only variants of unknown
signiﬁcance. How these ﬁndings might improve the sen-
sitivity of early diagnosis needs further elucidation, but
they may suggest novel therapeutic approaches, since
normalization of an impaired stroma can alter and po-
tentially reverse preneoplastic or maybe even neoplastic
breast epithelium.
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